The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

sealanebio.com

About Sea Lane Biotechnologies

The Sea Lane Biotechnologies fully human bio-therapeutic platform technologies provide unique solutions for pressing therapeutic needs. The company's technologies and inventions include the unique therapeutic class of entities known as Surrobodies and world-class human antibody libraries. Each represents a bio-therapeutic platform which may be leveraged externally, via partnerships, or or through internal discovery and development efforts to meet the requirements of creating a competitive product candidate pipeline and portfolio.

Sea Lane Biotechnologies Headquarter Location

Redwood City, California,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Sea Lane Biotechnologies Patents

Sea Lane Biotechnologies has filed 15 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/22/2016

2/26/2019

Molecular biology, Immune system, Proteins, Immunology, Clusters of differentiation

Grant

Application Date

1/22/2016

Grant Date

2/26/2019

Title

Related Topics

Molecular biology, Immune system, Proteins, Immunology, Clusters of differentiation

Status

Grant

Latest Sea Lane Biotechnologies News

i2 Pharma acquires antibody, protein engineering tech from Sea Lane Biotechnologies

Jun 1, 2017

Thursday June 1, 2017 0 comments Tags: Boulder , i2 Pharmaceuticals , Sea Lane Biotechnologies , Bruce Eaton , surrobodies BOULDER -- i2 Pharmaceuticals, Inc. , a biopharmaceutical company focused on next-generation discovery and development of therapeutics with a focus on personalized cancer treatment, announced the acquisition of all of the antibody and engineered protein technology of California-based Sea Lane Biotechnologies , including several potential product candidates. Financial details of the acquisition were not disclosed. I2 said the acquisition consists of three distinct classes of protein therapeutics, including world-class human antibody libraries, human b-cell derived antibodies, and a new class of engineered protein therapeutics called Surrobodies. Surrobodies allow for the facile creation of bi-specific therapeutic agents from vast arrays of monospecific agents, the company said. In addition, this new class of protein can be readily transformed by coupling small molecule drugs to Surrobodies to create Surrobody Drug Conjugates (SDCs), the next generation in potent cancer therapeutics. "We are thrilled with the acquisition of the product candidates and technologies so exquisitely crafted at Sea Lane,” said Dr. Bruce Eaton, i2’s founder, chair and CEO. “In particular, the antibodies and Surrobodies developed by Sea Lane for Immuno-Oncology (IO) complement existing programs at i2 Pharma in the development of cancer therapeutics. "We are now uniquely positioned with protein, small molecule and RNA therapeutic modalities that can be mixed and matched to innovate beyond the traditional boundaries of drug discovery with a goal of developing next generation, highly efficacious, cost-effective personalized therapeutics. "     Richard Lerner, the Lita Annenberg Hazen Professor of Immunochemistry and former president of The Scripps Research Institute, said he believes strongly in the capabilities of the Surrobody technology. "The Surrobody technology was created as an alternative to conventional antibody based approaches, with the potential for a wide range of protein engineering advantages,” Lerner said. “The Sea Lane Biotechnologies team and their commercial and academic partners clearly demonstrated the power of the Surrobody technology for many applications including multi-specific and drug conjugate formats. “With this acquisition, i2 Pharmaceuticals now has a compelling portfolio of Surrobody and antibody product candidates and technologies to add to its other exciting capabilities," Lerner said. "We are excited about the combination of the Sea Lane technologies and product candidates with i2 Pharma's existing portfolio of transformative technologies for drug discovery," said Lawrence Horowitz, CEO of Sea Lane Biotechnologies. "We share the vision at i2 Pharmaceuticals and their highly competent team. Our shared goal is efficacious, cost effective personalized therapeutics with a positive impact on patient lives. The combination of Sea Lane and i2 Pharma technologies can make that happen," said Michael Horowitz, Chief Operating Officer of Sea Lane Biotechnologies.

  • Where is Sea Lane Biotechnologies's headquarters?

    Sea Lane Biotechnologies's headquarters is located at Redwood City.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.